HC Wainwright Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $13.00

PDS Biotechnology (NASDAQ:PDSB) had its price objective decreased by research analysts at HC Wainwright from $21.00 to $13.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

PDS Biotechnology Stock Down 0.4 %

Shares of PDSB traded down $0.01 on Thursday, hitting $1.24. The company’s stock had a trading volume of 188,746 shares, compared to its average volume of 645,391. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $47.17 million, a price-to-earnings ratio of -1.06 and a beta of 1.68. The firm’s fifty day moving average price is $1.41 and its 200-day moving average price is $2.18. PDS Biotechnology has a fifty-two week low of $1.13 and a fifty-two week high of $4.56.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.10. On average, equities research analysts expect that PDS Biotechnology will post -1.2 EPS for the current year.

Institutional Investors Weigh In On PDS Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in shares of PDS Biotechnology by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after buying an additional 37,142 shares during the last quarter. Blair William & Co. IL boosted its position in PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after purchasing an additional 35,757 shares during the last quarter. Renaissance Technologies LLC boosted its position in PDS Biotechnology by 331.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock valued at $163,000 after purchasing an additional 76,800 shares during the last quarter. XTX Topco Ltd grew its stake in PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after purchasing an additional 47,528 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after purchasing an additional 48,132 shares in the last quarter. 26.84% of the stock is currently owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.